Hubei Hongyuan Pharmaceutical Technology Co Ltd banner
H

Hubei Hongyuan Pharmaceutical Technology Co Ltd
SZSE:301246

Watchlist Manager
Hubei Hongyuan Pharmaceutical Technology Co Ltd
SZSE:301246
Watchlist
Price: 24.3 CNY -0.41% Market Closed
Market Cap: ¥6.5B

Hubei Hongyuan Pharmaceutical Technology Co Ltd
Investor Relations

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. principally engages in the research, development, production, and sale of organic chemical raw materials, pharmaceutical intermediates, raw materials, and pharmaceutical preparations. The company is headquartered in Huanggang, Hubei and currently employs 2,164 full-time employees. The company went IPO on 2023-03-20. The firm is also engaged in the production of lithium hexafluorophosphate, one of the main materials for lithium battery electrolyte. The firm's main products are divided into organic chemical raw materials such as glyoxal in the ethylene glycol reaction chain, pharmaceutical intermediates such as glyoxylic acid, 2-methyl-5-nitroimidazole and other products, and raw materials such as metronidazole; Pharmaceutical intermediates guanine, diacetylguanine and other products in the reaction chain of methyl cyanoacetate and guanidine hydrochloride. The firm distributes its products in the domestic market and overseas markets.

Show more
Loading
301246
Shanghai Composite
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Shuangxi Xu
Director and General Manager
No Bio Available
Mr. Kefeng Zeng
Financial Director
No Bio Available
Mr. Yonghua Xiao
Director
No Bio Available
Mr. Siyuan Cheng
Deputy GM & Non-Independent Director
No Bio Available

Contacts

Address
HUBEI
Huanggang
No. 8, Hongyuan Road, Economic Development Zone, Fengshan Town, Luotian County
Contacts
+867135109598
www.hbhypharm.com
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett